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OBJECTIVES The purpose of this study was to determine whether the mortality benefit of intravenous
streptokinase administered within 4 h of the onset of acute myocardial infarction is
maintained at 12 years, and whether Thrombolysis in Myocardial Infarction (TIMI) flow
grades independently influence late survival.
BACKGROUND Treatment with reperfusion therapies and achievement of TIMI 3 flow are associated with
increased short- and medium-term survival after infarction. Whether infarct artery flow
independently influences survival more than five years after infarction is unknown.
METHODS The late survival of patients randomized to receive either streptokinase (1,500,000 IU over 30
to 60 min) or a matching placebo within 4 h of symptom onset in 1984–1986 was
determined. Angiography was performed in surviving patients at three to four weeks, and
TIMI flow grades were assessed blind to randomization and outcomes. The late vital status
was determined in 99% of patients.
RESULTS Patients randomized to receive streptokinase (n 5 107) had improved survival compared with
those randomized to placebo (n 5 112) at five years (84% vs. 70%; p 5 0.023) and 12 years
(66% vs. 51%; p 5 0.022). At five years 94% of patients with TIMI grade 3 flow, 81% of those
with TIMI grade 2 flow and 72% of those with TIMI grade 0–1 flow survived (p 5 0.005).
At 12 years 72% of patients with TIMI 3, 67% of those with TIMI 2 and 54% of those with
TIMI 0–1 flow survived (p 5 0.023). Multivariate analysis identified the ejection fraction (p 5
0.014), exercise duration (p 5 0.013) and TIMI 3 flow (p 5 0.04 compared with TIMI 0–2 flow)
as important factors for five-year survival. At 12 years multivariate predictors of late survival were
the ejection fraction (p 5 0.006), exercise duration (p 5 0.003) and myocardial score (p 5 0.013).
The end-systolic volume index was similar to the ejection fraction as a predictor of survival at five
and 12 years.
CONCLUSIONS The survival benefits of streptokinase persist for 12 years after infarction. TIMI flow at three
to four weeks is an independent predictor of five-year survival. (J Am Coll Cardiol 1999;34:
62–9) © 1999 by the American College of Cardiology
The rationale for the use of thrombolytic therapy in acute
myocardial infarction is that rapid reestablishment of coro-
nary blood flow distal to the culprit lesion reduces infarct
size, preserves left ventricular function and hence increases
survival (1–4). The efficacy of reperfusion achieved by
different thrombolytic strategies at 90 min varies (5–8),
though by 3 h most thrombolytic regimens achieve 70% to
80% patency of infarct-related arteries, and this degree of
patency is maintained at one and three weeks (3,5,9,10).
The completeness of reperfusion of the infarct-related
artery has prognostic significance, and Thrombolysis in
Myocardial Infarction (TIMI) grade 3 flow (normal flow) in
the infarct-related artery (9) has been shown to be associ-
ated with a better prognosis at 30 days than TIMI 0–2 flow
(no or slow filling) (11). At five years after infarction,
patients who had TIMI 2 flow at hospital discharge have
been reported to have a similar prognosis to that of patients
with an occluded infarct-related artery (12).
The Second International Study of Infarct Survival has
reported parallel survival curves at 10 years (13) in patients
randomized to receive either streptokinase or placebo,
whereas the Western Washington study appeared to show
convergence at eight years (14). These studies did not
determine the influence of TIMI flow on late survival. We
have previously reported the important prognostic influence
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of infarct-related artery patency for up to five years after a
first infarction in patients treated with thrombolytic therapy
(15), 23% of whom are included in this study.
In this study we aimed to determine whether improved
survival persisted for up to 12 years after randomization to
treatment with intravenous streptokinase versus placebo,
and whether the TIMI flow grade at three to four weeks
influenced late survival.
METHODS
Study population. Consecutive consenting patients aged
#70 years who presented within 4 h after the onset of chest
pain lasting $30 min were randomized to receive either
intravenous streptokinase (1,500,000 IU over 30 to 60 min)
or a matching placebo from August 1984 through August
1986 (3). Eligible patients required ST-segment elevation of
$1 mm on the admission electrocardiogram in at least two
contiguous leads (limb leads or V4–V6), or $2 mm in leads
V1–V3 (16). The exclusion criteria have been previously
reported (3). The trial was approved by the local ethics
committee, which required written informed consent.
Treatment regimen. A 48-h infusion of intravenous heparin
(1,000 IU/h) was commenced after the infusion of streptoki-
nase or placebo, with adjustment of the activated partial
thromboplastin time to 2–2.5 3 normal. Aspirin (50 mg) and
dipyridamole (400 mg daily) were administered until angiog-
raphy. Intravenous propranolol (0.1 mg/kg over 5 min) was
recommended and was received by 47% of patients. Oral
beta-adrenergic blocking agents were commenced on days 2–3
in the absence of contraindications; 66% were receiving this
therapy at angiography. Calcium antagonists and nitrates were
prescribed for postinfarction angina. After angiography, med-
ication was at the physician’s discretion. Patients were advised
to stop smoking, to exercise regularly, to reduce weight and to
consume a low fat diet. Exercise testing on the Bruce protocol
was performed at three to four weeks.
Cardiac catheterization. Biplane ventriculography and
coronary angiography were performed three to four weeks
after infarction (median 25 days [interquartile range 21 to
32]) unless refractory ischemia necessitated earlier investi-
gation. Ventricular volumes and ejection fractions were
calculated and regional wall motion was assessed as previ-
ously described (3,17). Infarct-related artery flow was as-
sessed in our core angiographic laboratory (8), blind to
treatment and clinical outcome, according to TIMI flow
grading (0 5 occluded, 1 5 penetration of contrast, 2 5
slow flow or contrast clearance, 3 5 normal filling) (9) and
corrected TIMI frame counting (18). The severity of coro-
nary artery disease was assessed according to the Coronary
Artery Surgery Study criteria (19) and the myocardial score,
which measures the amount of myocardium supplied as well as
the severity of coronary stenoses (20). Revascularization was
performed for left main coronary artery disease or refractory
angina despite medical therapy.
Follow-up. Late follow-up was done either by recall to the
clinic, by the family doctor or by telephone or mail. The
mortality status of patients was determined in 99.1% at five
years and 94.0% at 10 years. End points were verified by source
documents. Deaths were classified as cardiac or noncardiac
(21). Reinfarction was defined as two of the following: pro-
longed ischemic chest pain, creatine kinase .2 times normal or
development of new Q waves on the electrocardiogram.
Late percutaneous or surgical revascularization and hospi-
talization for other cardiovascular causes were also recorded.
Statistical analysis. Baseline characteristics are expressed
as mean 6 SD or percentages. Survival curves were con-
structed using the Kaplan-Meier method and compared
using Mantel and Haenszel log-rank tests, with no impu-
tations for deaths before angiography. Multivariate analysis
of survival was performed using Cox proportional hazards
Abbreviations and Acronyms
ECSG 5 European Cooperative Study Group
TIMI 5 Thrombolysis in Myocardial Infarction















Age (yr) 57.4 (8.0) 56.2 (8.5) 0.27 56.7 (8.8) 56.1 (8.7) 56.2 (7.3) 0.9
Male gender 79% 73% 0.25 77% 69% 81% 0.36
Smoking* 74% 82% 0.16 85% 73% 76% 0.19
Diabetes mellitus 8% 12% 0.33 6% 10% 11% 0.53
Hypertension 34% 24% 0.09 28% 27% 30% 0.91
Beta-blocker therapy† 30% 17% 0.03 21% 18% 30% 0.27
Previous infarction 16% 27% 0.07 17% 18% 25% 0.44
Previous CABG 3% 1% 0.32 1% 2% 3% 0.71
Total cholesterol (mmol/liter) 6.1 (1.3) 6.1 (1.8) 0.70 6.3 (1.5) 5.9 (1.5) 6.1 (1.5) 0.41
HDL cholesterol (mmol/liter) 0.96 (0.3) 1.0 (0.3) 0.22 1.0 (0.3) 1.0 (0.4) 0.93 (0.3) 0.24
*Currently smoking or quit ,1 year previously. †At admission.
CABG 5 coronary artery bypass grafting; HDL 5 high density lipoprotein; TIMI 5 Thrombolysis in Myocardial Infarction flow grade.
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regression methods, and the assumption of proportional
hazards was satisfied for variables in final models. All factors
in Table 4 (univariate analysis) were included in the initial
models. Continuous variables, including exercise duration,
were compared by one-way analysis of variance, and discrete
variables were compared by the chi-square test with Yates’
correction where appropriate, with the level of significance
being p 5 0.05.
RESULTS
Patients were randomized to receive either streptokinase
(n 5 107) or placebo (n 5 112); their baseline characteris-
tics are shown in Table 1. Angiography was performed in
194 patients and 186 underwent exercise testing (Table 2).
Eighteen patients (14 placebo) died before angiography,
seven patients refused angiography (two for medical rea-
sons) and three patients were not catheterized because of
stroke, pneumonia and esophageal rupture, respectively.
Late outcome. During follow-up for a median of 9.9 years
(interquartile range 4.7 to 10.8 years), there were 67 cardiac
deaths and 45 nonfatal myocardial infarctions. There were
24 noncardiac deaths (13 streptokinase and 11 placebo), of
which eight were due to stroke (one placebo and seven
streptokinase). Between five and 12 years there were 24
cardiac deaths (14 placebo and 10 streptokinase) and 15
noncardiac deaths (seven placebo and eight streptokinase).
At five years 84% of the streptokinase group and 70% of the
placebo group survived (p 5 0.023), and at 12 years 66% of
the streptokinase group and 51% of the placebo group
survived (p 5 0.022) (Fig. 1). During follow-up, 47 patients
(22%) underwent coronary revascularization (40 coronary
artery surgery and seven angioplasty). The coronary revas-
cularization rates at 1 and 5 years were 10% (8% streptoki-
nase and 11% placebo) and 14% (13% streptokinase and
14% placebo), respectively. The event-free survival at 12
years (freedom from death, recurrent infarction or revascu-
larization) was 38% (streptokinase 45% and placebo 31%,
p 5 0.032).
At follow-up there were no differences between the
streptokinase and placebo groups in terms of angina class
(0.9 6 1.1 vs. 0.8 6 1.0; p 5 0.58), aspirin therapy (66% vs.
63%; p 5 0.8) or beta-blocker therapy (48% vs. 45%; p 5
0.9). There were no differences in these variables with respect
to TIMI flow grades at three to four weeks (not shown).
Figure 1. Late actuarial survival after randomization to receive streptokinase or placebo after myocardial infarction. The log-rank
comparison between the streptokinase and placebo groups was p 5 0.022. At 5 years survival was 84% (95% confidence interval [CI] 76
to 90) in the streptokinase group and 70% (95% CI 60 to 77) in the placebo group (p 5 0.023). At 12 years, survival was 66% (95% CI
55 to 75) in the streptokinase group and 51% (95% CI 41 to 60) in the placebo group (p 5 0.022).







TIMI 3 flow (%) 41 44
TIMI 2 flow (%) 21 30 0.15*
TIMI 0–1 flow (%) 38 26
Left main stenosis (%) 5 3 0.50
Myocardial score 8.9 6 2.7 8.4 6 2.8 0.29
Infarct artery LAD (%) 36 39 0.74
Ejection fraction (%) 50.7 (13.8) 53.6 (13.3) 0.15
ESV index (ml/m2) 42.6 (25.2) 37.4 (21.0) 0.12
EDV index (ml/m2) 81.9 (31.3) 77.5 (24.8) 0.28
Regional wall motion 5.01 (3.6) 4.21 (3.3) 0.11
*p value indicates three-way comparison; p 5 0.10 for two-way comparison of TIMI
2–3 vs. TIMI 0–1 flow.
EDV 5 end-diastolic volume index; ESV 5 end-systolic volume index; LAD 5 left
anterior descending coronary artery; TIMI 5 Thrombolysis in Myocardial Infarction.
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Thrombolysis in Myocardial Infarction flow and late
survival. At five years the survival rate among patients who
had undergone angiography was 84%, (TIMI 3 flow 94%,
TIMI 2 flow 81%, TIMI 0–1 flow 72%; p 5 0.005
[three-way log-rank comparison]), and at 12 years the
survival rate was 65% (TIMI 3 flow 72%, TIMI 2 flow 67%,
TIMI 0–1 flow 54%; p 5 0.024) (Fig. 2). The two-way
log-rank comparisons of TIMI 3 versus TIMI 2 flow at five
and 12 years were p 5 0.045 and p 5 0.36, respectively. Of
82 patients with TIMI 3 flow, 36 had corrected TIMI frame
counts of #27 and 18 had frame counts of .40 (Table 3).
Of 49 patients with TIMI 2 flow, 8 had frame counts of
#27 and 34 had frame counts of .40. Corrected TIMI
frame counts at cut points of either 27 or 40 frames did not
influence survival in the 131 patients with patent arteries.
Predictors of late death. Univariate predictors of survival
at five and 12 years included the end-systolic volume index,
ejection fraction, treadmill exercise time (all p , 0.001),
TIMI flow grade, myocardial score, randomization to re-
ceive streptokinase and no diabetes mellitus (all p , 0.05)
(Table 4). On multivariate analysis using Cox proportional
hazards models, independent predictors of five-year survival
were the ejection fraction (p 5 0.014), treadmill exercise
time (p 5 0.013) and TIMI 3 flow (p 5 0.04) (Table 5). At
12 years after infarction the ejection fraction (p 5 0.006),
treadmill exercise time (p 5 0.003) and myocardial score
Figure 2. Late survival after myocardial infarction according to the Thrombolysis in Myocardial Infarction (TIMI) flow grade at 3 to 4
weeks. (A) The log-rank three-way comparisons between TIMI 3, 2 and 0–1 flow, truncated at 1, 5 and 12 years, were p 5 0.005, 0.005
and 0.028, respectively. The log-rank two-way comparisons of TIMI 3 versus TIMI 2 flow at 1, 5, and 12 years were p 5 0.047, 0.045
and 0.36, respectively. The log-rank two-way comparisons of TIMI 3 versus TIMI 0–1 flow, truncated at 1, 5 and 12 years, were p 5
0.001, 0.0009 and 0.006, respectively. The log-rank two-way comparisons of TIMI 0–1 versus TIMI 2 flow, truncated at 1, 5 and 12 years,
were p 5 0.22, 0.25 and 0.15, respectively. (B) Survival adjusted for the ejection fraction and exercise duration; the log-rank comparisons,
truncated at 5 and 12 years, were p 5 0.026 and 0.27, respectively.
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(p 5 0.013) were multivariate factors predictive of survival;
TIMI flow grade was not an independent predictive factor.
The end-systolic volume index was similar to the ejection
fraction as a predictor of survival at five and 12 years.
DISCUSSION
We observed that survival after acute myocardial infarction
was improved up to 12 years after randomization to receive
intravenous streptokinase compared with placebo. The
TIMI flow grade, assessed at three to four weeks, was an
independent prognostic factor for five-year survival, and
patients with TIMI 2 flow had a survival rate intermediate
between that of patients with TIMI 3 and those with TIMI
0–1 flow. In 1994 we reported the prognostic importance at
39 months of a patent infarct-related artery (15) in patients
randomized to receive thrombolytic therapy with streptoki-
nase versus either placebo (3) or tissue plasminogen activa-
tor (22); 23% of those patients are included in the current
study.
Effect of thrombolytic therapy on late survival. The
survival curves remained parallel at 12 years, indicating a
persisting survival benefit among patients randomized to
receive streptokinase (p 5 0.02). Other studies have re-
ported a sustained benefit of intravenous streptokinase at up
to five years (2,13,14,23), though survival was not improved
at eight years in the Western Washington studies of
intravenous and intracoronary streptokinase (p 5 0.16) (14).
The Second International Study of Infarct Survival and
Gruppo Italiano per lo Studio della Streptochinasi
nell’Infarto Miocardico studies, which included patients
with non–ST-elevation infarction, have shown parallel sur-
vival curves to 10 years (24,25), as have data from the Dutch
Interuniversity study (26), extending to 10 to 14 years.
Infarct artery flow and late outcome. The five-year mor-
tality benefit of a patent infarct-related artery (15), partic-
ularly with TIMI 3 flow, has been extended by the obser-
vations reported here. The benefit of TIMI 3 flow was
maintained after adjustment for ventricular function (either
the end-systolic volume index or ejection fraction) and
treadmill exercise time. TIMI 3 flow was associated with
increased survival at 12 years on univariate analysis, but not
after adjustment for other independent prognostic factors,
which may be due to beta error. Also, progression of
coronary artery disease in the non–infarct-related arteries
(evidenced by the independent influence of the myocardial
score on 12-year survival), the effects of revascularization
and noncardiac disease in an aging population may all have
influenced the prognostic effects of infarct artery flow on
survival at 12 years.
In this study, survival at five years for patients with TIMI
3 flow was 94% compared with 91% reported by the
European Cooperative Study Group (ECSG) (12). In
patients with occluded infarct-related arteries (TIMI 0–1
flow), the five-year survival was 72% compared with 84% in
the ECSG study (12), which may in part reflect a more
conservative approach to revascularization in New Zealand
—10% at one year and 14% at five years, compared with
approximately 20% at one year reported by the ECSG (12).
In our study, TIMI 2 flow, assessed in a core laboratory
setting, was associated with a survival rate at five and 12
years that was intermediate between that of TIMI 3 and
TIMI 0–1 flow. These findings contrast with those re-
ported by the ECSG (12) showing five-year survival benefits
of TIMI 3 flow assessed 10 to 22 days after infarction, but
not TIMI 2 flow, which tracked with TIMI 0–1 flow.
There may be significant differences in TIMI 2 flow
assessment between local and core angiographic laboratories
(18). Also, the two-year survival of patients who had had
TIMI 2 flow at 90 6 45 min in the Global Use of Strategies








CTFC #27 36 8 — 44
CTFC 27–40 28 6 — 34
CTFC .40 18 34 — 52
Occluded — — 63 63
Total 82 49* 63 194*
*One patient with TIMI 2 flow and coronary artery dissection did not have a CTFC.
Among patients with patent infarct arteries, 62% of those with LAD infarcts (n 5 55)
vs. 63% of those with non-LAD infarcts (n 5 76) had TIMI 3 flow (p 5 NS); and
34 (62%) of those with LAD infarcts vs. 44 (58%) of those with non-LAD infarcts
had a CTFC of ,40 (p 5 NS).
CTFC 5 corrected TIMI frame count; LAD 5 left anterior descending coronary
artery; TIMI 5 Thrombolysis in Myocardial Infarction.
Table 4. Univariate Predictors of Late Mortality





Age 2.72 0.1 9.51 0.002
Gender 0.00 0.96 0.72 0.40
Diabetes 5.57 0.02 3.69 0.05
Hypertension 0.84 0.36 1.93 0.17
Smoking 1.50 0.22 2.11 0.13
Streptokinase 6.27 0.012 5.40 0.02
Exercise time 13.60 , 0.001 18.60 , 0.001
Ejection fraction 14.30 , 0.001 22.20 , 0.001
EDV index 11.00 , 0.001 8.10 0.002
ESV index 16.00 , 0.001 15.60 , 0.001
TIMI 3 flow 11.90 , 0.001 5.09 0.03
Number of vessels 3.03 0.082 8.68 0.003
Myocardial score 7.32 0.007 19.4 , 0.001
Total cholesterol
(mmol/liter)
0.14 0.71 0.3 0.58
HDL cholesterol
(mmol/liter)
0.00 0.95 1.22 0.27
EDV 5 end-diastolic volume; ESV 5 end-systolic volume; HDL 5 high density
lipoprotein; TIMI 5 Thrombolysis in Myocardial Infarction.
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to Open Occluded Coronary Arteries trial (27) was not
significantly better than that of patients with TIMI 0–1
flow, but those data were not adjusted for baseline risk.
Corrected TIMI frame counting has been reported to
provide a more reproducible assessment of infarct-related
artery flow than TIMI flow grading does (18). There were
insufficient patients with patent arteries (n 5 131) to
undertake statistical analysis in order to determine whether
frame counting was superior to TIMI flow grading.
Half the patients reported here were randomized to
receive a placebo infusion on a background of aspirin and
heparin therapy. At three to four weeks the patency rate
(TIMI 2–3 flow) in these patients was 61%, similar to the
73% patency rate in patients receiving streptokinase. In
patients not treated with thrombolytic therapy the infarct-
related artery is usually occluded in the first few hours after
myocardial infarction (28), but in the subsequent 24 h
recanalization may occur either spontaneously or as a result
of antithrombotic and antiplatelet therapy (29). The rate of
reocclusion of patent arteries is 10% to 15% in the two
weeks after myocardial infarction despite regular aspirin
therapy (29).
Ventricular function and survival. We have previously
shown in non–thrombolytic-treated patients that end-
systolic volume was a more powerful predictor of outcome
than ejection fraction. Here the end-systolic volume index
and the ejection fraction were similar in predicting five- and
12-year survival (3,30). Migrino et al. (31) highlighted the
importance of an end-systolic volume index of 40 ml/m2 at
90 or 180 min for predicting one-year mortality. Also, there
was an interaction between ventricular volume and the
frequency of patients achieving TIMI 3 flow, with only
about 30% of patients having TIMI 3 flow with volumes
above this figure (31). Late revascularization of occluded
infarct-related arteries may have beneficial effects on remod-
eling and end-systolic volume, although this has not been
evaluated in randomized trials (32).
Other factors. The Gruppo Italiano per lo Studio della
Streptochinasi nell’Infarto Miocardico group (33) has re-
ported the influence of exercise test performance on mor-
tality at six months. Here we report that exercise time is
independently associated with both five- and 12-year out-
comes; the ECSG (12) indicated similar findings at five
years. We did not detect any influence of baseline total or
high density lipoprotein cholesterol on late outcome. Al-
though all patients received dietary advice, the general use of
lipid-modifying drugs after infarction was not widespread
during the follow-up period of 1984–1996. The Scandina-
vian Simvastatin Survival Study (34) was published toward
the end of our follow-up, and thus any resulting changes to
clinical practice would have had minimal impact.
Study limitations. This study did not determine the effect
on late mortality of TIMI flow grades assessed early after
symptom onset. The TIMI flow results reported at three to
four weeks represent the net effects of reperfusion and
reocclusion in patients treated with 50 mg of aspirin and
400 mg of dipyridamole, intravenous heparin for 48 h and
intravenous streptokinase or placebo. In this study strep-
tokinase was administered for 30 to 60 min to patients aged
#70 years presenting within 4 h of symptom onset, though
this regimen has not been formally tested in large clinical
trials. Streptokinase continued to be used widely even when
thrombolytics were provided free in a large clinical trial (35).
Aspirin doses of ,150 mg daily have not been tested in
large clinical trials of myocardial infarction, though anti-
platelet therapy with aspirin (50 mg) and dipyridamole
(400 mg), as used in this study, has been shown to be
beneficial in other manifestations of cardiovascular disease,
for example, in reducing stroke and preventing saphenous
vein graft occlusion (36,37). However, the Coumadin As-
pirin Reinfarction Study (38), which used 80 mg of aspirin
in combination with 1 or 3 mg of warfarin, or 160 mg of
aspirin alone for five years, found no difference in the
subsequent rates of reinfarction, nonfatal ischemic stroke or
cardiovascular death between these groups.
Additionally, beta-blocker therapy could be used more
frequently than the rates of 47% intravenously and 66%
orally used in our patients. There have been changes to
medical care after infarction in the last decade, including
new thrombolytic therapies, the use of lipid-modifying











Ejection fraction* 0.014 27.3 3 , 0.001
Exercise time 0.013
TIMI 3 flow 0.040
12-year mortality
Ejection fraction* , 0.006 40.6 3 , 0.001
Exercise time , 0.003
Myocardial score 0.013
*If the end-systolic volume index was substituted for the ejection fraction, the chi-square (model) was 27.1 at five years and 36.8
at 12 years.
TIMI 5 Thrombolysis in Myocardial Infarction.
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drugs, angiotensin-converting enzyme inhibition and differ-
ent rates of revascularization, which may also have influ-
enced the results of this study.
Conclusions. The survival and event-free survival benefits
of thrombolytic therapy with intravenous streptokinase are
sustained at 12 years. The TIMI flow grade at three to four
weeks after myocardial infarction is an important predictor
of late outcome, as are ventricular function and exercise
duration. Whether outcomes are improved by revasculariza-
tion or adjunctive medical therapies, such as direct thrombin
inhibitors, low molecular weight heparins and glycoprotein
IIb/IIIa receptor antagonists, in patients without TIMI 3
flow in the infarct-related artery is unknown.
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